GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pheton Holdings Ltd (NAS:PTHL) » Definitions » Current Ratio

PTHL (Pheton Holdings) Current Ratio : 12.39 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Pheton Holdings Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Pheton Holdings's current ratio for the quarter that ended in Dec. 2024 was 12.39.

Pheton Holdings has a current ratio of 12.39. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Pheton Holdings's Current Ratio or its related term are showing as below:

PTHL' s Current Ratio Range Over the Past 10 Years
Min: 0.44   Med: 4.27   Max: 12.39
Current: 12.39

During the past 4 years, Pheton Holdings's highest Current Ratio was 12.39. The lowest was 0.44. And the median was 4.27.

PTHL's Current Ratio is ranked better than
95.16% of 868 companies
in the Medical Devices & Instruments industry
Industry Median: 2.58 vs PTHL: 12.39

Pheton Holdings Current Ratio Historical Data

The historical data trend for Pheton Holdings's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pheton Holdings Current Ratio Chart

Pheton Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Current Ratio
7.47 1.06 0.44 12.39

Pheton Holdings Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Current Ratio Get a 7-Day Free Trial 1.06 0.60 0.44 0.23 12.39

Competitive Comparison of Pheton Holdings's Current Ratio

For the Medical Devices subindustry, Pheton Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pheton Holdings's Current Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pheton Holdings's Current Ratio distribution charts can be found below:

* The bar in red indicates where Pheton Holdings's Current Ratio falls into.


;
;

Pheton Holdings Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Pheton Holdings's Current Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Current Ratio (A: Dec. 2024 )=Total Current Assets (A: Dec. 2024 )/Total Current Liabilities (A: Dec. 2024 )
=6.678/0.539
=12.39

Pheton Holdings's Current Ratio for the quarter that ended in Dec. 2024 is calculated as

Current Ratio (Q: Dec. 2024 )=Total Current Assets (Q: Dec. 2024 )/Total Current Liabilities (Q: Dec. 2024 )
=6.678/0.539
=12.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pheton Holdings  (NAS:PTHL) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Pheton Holdings Current Ratio Related Terms

Thank you for viewing the detailed overview of Pheton Holdings's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pheton Holdings Business Description

Traded in Other Exchanges
N/A
Address
Hong Jun Ying South Road, Room 306, NET Building, Chaoyang District, Beijing, CHN, 100101
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.

Pheton Holdings Headlines